What is Xtovia?
Xtovia operates at the intersection of biotechnology and consumer wellness, specializing in advanced hair repair solutions. The company's core value proposition is anchored in its patent-pending TriLayerX™ HairTech, a proprietary system designed to address structural hair damage from the core to the cuticle. Unlike conventional brands that rely on surface-level cosmetic fixes, Xtovia utilizes molecular science to deliver measurable results. By maintaining an end-to-end internal process—from initial research and formulation to clinical testing and manufacturing—the brand ensures rigorous quality control and scientific integrity. This vertically integrated approach allows Xtovia to maintain a competitive edge in the Indian market while establishing a scalable model for global expansion.
How much funding has Xtovia raised?
Xtovia has raised a total of $732K across 1 funding round:
Angel/Pre-Seed
$732K
Angel/Pre-Seed (2026): $732K with participation from Atrium and V3 Ventures
Key Investors in Xtovia
Atrium
Atrium is a venture capital firm that connects founders with capital and support, focusing on early-stage startups through various specialized funds.
V3 Ventures
V3 Ventures is an investment firm that supports founders in building innovative consumer brands across wellness and lifestyle sectors, backed by Verlinvest.
What's next for Xtovia?
With the successful closure of this major strategic investment, Xtovia is poised to accelerate its research and development pipeline, further refining its TriLayerX™ technology. The company's strategic roadmap likely includes scaling its manufacturing capabilities to meet rising demand and broadening its distribution channels to reach a wider demographic of science-conscious consumers. As the brand transitions from its early-stage development phase into a period of rapid market penetration, the focus will remain on leveraging clinical data to solidify its reputation as a leader in high-performance haircare. Future growth will likely be driven by continued investment in molecular research and the potential introduction of new product lines that adhere to the company's stringent standards for efficacy and innovation.
See full Xtovia company page
